Role of neurotrophin and neuropeptides in bronchial asthma;Rola neurotrofiny i neuropeptydów w patogenezie astmy oskrzelowej

Polski Merkuriusz Lekarski

Volumn 16, Issue 92, 2004, Pages 101-103

  Pałgan, Krzysztof ^a,b   Dziedziczko, Andrzej ^a  

^a AM   (Poland)

^b Katedra i Klinika Alergologii   (Poland)

Author keywords

Bronchial asthma; Neuropeptides; Neurotrophin

Indexed keywords

CALCITONIN GENE RELATED PEPTIDE; NEUROKININ A; NEUROPEPTIDE; NEUROTROPHIN; SUBSTANCE P;

ASTHMA; BASOPHIL; BRONCHUS HYPERREACTIVITY; BRONCHUS MUCOSA; CELL DIFFERENTIATION; CELL MIGRATION; EOSINOPHIL; HUMAN; MACROPHAGE; MAST CELL; MAST CELL DEGRANULATION; NEUTROPHIL; REVIEW; T LYMPHOCYTE;

ASTHMA; CALCITONIN GENE-RELATED PEPTIDE; HUMANS; NERVE GROWTH FACTOR; NEUROKININ A; NEUROPEPTIDES; SUBSTANCE P;

EID: 1642272836     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Adamko D.J. i wsp.: Ovoalbumin sensitization changes the inflammatory response to subsequent parainfluenza infection. Eosinophils mediate airway hyperresponsiveness, m(2) muscarinic receptor dysfunction, and antiviral effects. J. Exp. Med., 1999, 190, 1465-1478.
2. Aloe L. i wsp.: The expending role of nerve growth factor: from nerotrophic activity to immunologic disease. Allergy, 1997, 52, 883-994.
3. Baesley R. i wsp.: Cellular events in the bronchi in mild asthma and after bronchial provocation. Am. Rev. Respir. Dis., 1989; 139, 806-817.
4. Baluk P. i wsp.: Upregulation of substance P receptors in angiogenesis associated with chronic airway inflammation in rats. Am. J. Physiol. Lung Cell Mol. Physiol., 1997, 273, L-565-L-571.
5. Braun A., Appel E., Baruch R.: Role of nerve growth factor in mouse model of allergic airway inflammation and asthma. Eur. J. Immunol., 1998, 28, 3240-3251.
6. Cartwright M. i wsp.: The human nerve growth factor gene: structure of the promotor region and expression in L929 fibroblasts. Mol. Brain. Res., 1992, 15, 67-75.
7. de Vries A. i wsp.: Nerve growth factor induces a neurokinin-1 receptor mediated airway hyperresponsiveness in guinea pigs. Am. J. Respir. Crit. Care Med., 1999, 159, 1541-1544.
8. Fryer A.D. i wsp.: Effects of inflammatory cells on neuronal M2 muscarinic receptor function in the lung. Life Sci., 1999, 64, 449-455.
9. Gu Q.H., Lee L.Y.: Hypersensitivity of pulmonary C fibre afferents induced by cationic proteins in the rat. J. Physiol, London, 2001, 537, 887-897.
10. Haslett C.: Granulocyte apoptosis and its role in the resolution and control of lung inflammation. Am. J. Respir. Crit. Care Med., 1999, 160, S511-S519.
11. Kassel O. i wsp.: Local increase in the number of must cells and expression of nerve growth factor in the bronchus of asthmatic patients after repeated inhalation of allergen at low-dose. Clin. Exp. Allergy, 2001, 31, 1432-1440.
12. Kraneveld A.D., Nijkamp F.P.: Tachykinins and neuro-immune interactions in asthma. Int. Immunopharmacol, 2001, 1, 1629-1650.
13. Kroegel C. i wsp.: Blood and bronchoalveolar eosinophils in allergic subjects after segmental antigen challenge: surface phenotype, density heterogeneity, and prostanoid production. J. Allergy Clin. Immunol., 1994, 93, 725-734.
14. Kumar P.K.: Understanding airway wall remodeling in asthma: a basis for improvements in therapy? Pharmacol. Ther., 2001, 91, 93-104.
15. Kwan M.L. i wsp.: Airway vasculature after mycoplasma infection: chronic leakiness and selective hypersensitivity to substance P. Am. J. Physiol. Lung Cell Mol. Physiol., 2001, 280, L286-397.
16. Laitinen L.A., Laitinen A., Heehtela T.: Airway mucosal inflammation even in patients with newly diagnosed asthma. Am. Rev. Respir. Dis., 1993, 147, 697-704.
17. Laliberté R., Rouabhia M., Bossé M., Chakir J.: Decreased caposity of asthmatic bronchial fibroblasts to degrade collagen. Matrix Biol., 2001, 19, 743-753.
18. Levi-Montalcini R.: The nerve grofth factor 35 years later. Science, 1987. 237, 1154-1162.
19. Lukacs N.W., Strieter R.M., Kunkel S.L.: Leukocyte infiltration in allergic airway inflammation. Am. J. Respir. Cell Mol. Biol., 1995. 13, 1-6.
20. Malis D.D., Lacroix J.S.: CGRP and other mediators of neurogenic inflammation at the level of the nasal mucosa. Schweizerische Medizinische Wochenschrift, 2000, 130, 96S-98S.
21. Malłolepszy J.: Epidemiologia chorób alergicznych w Polsce. Astma, Alergologia i Immunologia Kliniczna, 2000, 5, supl. 5.
22. McDonald D.: Angiogenesis and remodeling of airway vasculature in chronic inflammation. Am. J. Respir. Crit. Care Med., 2001, 164, S39-S45.
23. Michel C.C., Neal C.R.: Openings though endothelial cells associated with incerased microvascular permeability. Microcirculation. 1999, 6, 45-54.
24. Olgart C., Frossard N.: Human lung fibroblasts secrete nerve growth factor: effect of inflammatory cytokines and glucocorticoids. Eur. Respir. J., 2001, 18, 115-121.
25. Olgart C., Frossard N.: Nerve growth factor and asthma. Eur. Respir. Rev., 2000, 10, 326-328.
26. Pałgan K. i wsp.: Rola komórek tucznych w reakcjach zapalnych. Pneumonol. Alergol. Pol., 2000, 68, 599-605.
27. Renz H.: The role of neurotrophins in bronchial asthma. Eur. J. Pharmacol., 2001, 429, 231-237.
28. Resnick MB., Weller PF.: Mechanisms of eosinophil recruitment. Am. J. Respir. Cell Mol. Biol., 1993, 8, 349-355.
29. Simone MD. i wsp.: Nerve growth factor: a survey of activity on immune and hematopoietic cells. Hematol. Oncol., 1999, 17, 1-10.
30. Tam S.Y. i wsp.: Expression of functional TrkA receptor tyrosine kinase in the HMC-1 human mast cells. Blood 1997, 90, 1807-1820.
31. Thurston G. i wsp.: Microvascular remodeling in chronic airway inflammation in mice. Clin. Exp. Pharmacol. Physiol., 2000, 27, 836-841.
32. Venge J. i wsp.: Identification of IL-5 and RANTES as the major eosinophil chemoattractants in the asthmatic lung. J. Allergy Clin. Immunol., 1996, 97, 110-1115.
33. Walker P. i wsp.: Effect of nerve growth factor (NGF) and other fibroblast-derived growth factors on immature mast cells, (HMC-1). Immunology, 1998, 94, 310-317.
34. Walsh D.T. i wsp.: Substance P-induced inflammatory responses in guineapig skin: the effect of specific NK1 receptor antagonists and the role of endogenous mediators. Br. J. Pharmacol., 1995, 114, 1343-1350.